Should I Buy REVB? REVB 2026 Analysis

Should You Buy Revelation Biosciences Inc (REVB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.190

1 Day change

5.31%

52 Week Range

44.770

Analysis Updated At

2026/03/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Revelation Biosciences Inc (REVB) is not a good buy for a beginner investor with a long-term strategy at this time. The stock lacks positive momentum, has weak financial performance, and no significant catalysts to support growth in the near term. Additionally, technical indicators and trading signals do not suggest a strong entry point.

Technical Analysis

The stock is showing bearish moving averages (SMA_200 > SMA_20 > SMA_5), with RSI at 34.143 in the neutral zone. MACD is slightly positive but contracting, indicating weak momentum. The pre-market price is $1.08, down 4.42%, and the stock is trading below key support levels (S1: 1.138, S2: 1.103).

Positive Catalysts

The Gemini trial safety data was well-tolerated at the target dose with mild adverse events, and the company has enough funding into Q1 2027.

Neutral/Negative Catalysts

The stock is down pre-market (-4.42%), financial performance is weak with no revenue growth and negative EPS (-1.64), and there is no recent news or significant trading activity from insiders, hedge funds, or Congress.

Financial Performance

In Q4 2025, the company reported no revenue growth (0% YoY), net income of -$2.51M (improved 45.5% YoY), and a significant drop in EPS to -1.64 (-97.25% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Roth Capital lowered the price target from $20 to $16 but maintained a Buy rating, citing sufficient funding into 2027 and positive trial safety data. However, this does not align with the stock's current bearish trend and weak financials.

Analyst Rating

Wall Street analysts forecast REVB stock price to rise

Buy

Hold

Sell

Current: 1.130

Low

Averages

High

Current: 1.130

Low

Averages

High

Roth Capital

Jonathan Aschoff

Buy

maintain

$16

AI Analysis

2026-03-30

New

Reason

Roth Capital

Jonathan Aschoff

Price Target

$16

AI Analysis

2026-03-30

New

maintain

Buy

Reason

Roth Capital analyst Jonathan Aschoff says Revelation Biosciences showed data from all Phase 1b PRIME trial patients showing that Gemini was similarly effective in reducing inflammatory cytokine levels, and restoring immunocompetence in chronic kidney disease patient peripheral blood mononuclear cells regardless of background inflammation levels. Gemini significantly reduced the number of elevated cytokines at all measured timepoints after a single dose out to seven days, the analyst tells investors in a research note. Roth says the results show Gemini's "broad effect." It keep a Buy rating on the shares with a $16 price target. The stock in late day trading is up 6% to $1.20.

Roth Capital

Buy

downgrade

$20 -> $16

2026-02-27

Reason

Roth Capital

Price Target

$20 -> $16

2026-02-27

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on Revelation Biosciences to $16 from $20 but keeps a Buy rating on the shares. The company ended 2025 with pro forma cash of $17.3M, enough funding into Q1 of 2027, the analyst tells investors in a research note. The firm further cites the Gemini trial safety data, which was well-tolerated at the target dose with all adverse events reported as mild at that dose and including transient headache, chills, loose stool, and body aches.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REVB

Unlock Now

REVB Should I Buy

REVB Should I Buy

Should You Buy Revelation Biosciences Inc (REVB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch